2002
DOI: 10.1089/152581602321080600
|View full text |Cite
|
Sign up to set email alerts
|

Acute Promyelocytic Leukemia M3: Cytomorphologic, Immunophenotypic, Cytogenetic, and Molecular Variants

Abstract: Acute promyelocytic leukemia (APL) M3 is an acute myeloid leukemia (AML) subtype characterized by proliferation of malignant promyelocytes with mature myeloid immunophenotype and the translocation t(15;17)(q22;q11), which results in the fusion of retinoic acid receptor-alpha (RARalpha) gene on chromosome 17 and the gene PML on chromosome 15. There are three M3 morphologic variants: the typical hypergranular form and the microgranular and basophilic variants. Although most leukemic cells in M3 patients express … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

4
17
0

Year Published

2004
2004
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(21 citation statements)
references
References 30 publications
4
17
0
Order By: Relevance
“…The resulting hybrid PML/RARα gene is involved in leukaemic transformation, as it encodes for a fusion protein that blocks myeloid cell differentiation at the promyelocytic stage [1]. The introduction of all- trans -retinoic acid (ATRA) as a tailored treatment of APL has markedly improved its prognosis; however, about 30% of the patients that achieve complete remission (CR) will eventually relapse [2, 3].…”
Section: Introductionmentioning
confidence: 99%
“…The resulting hybrid PML/RARα gene is involved in leukaemic transformation, as it encodes for a fusion protein that blocks myeloid cell differentiation at the promyelocytic stage [1]. The introduction of all- trans -retinoic acid (ATRA) as a tailored treatment of APL has markedly improved its prognosis; however, about 30% of the patients that achieve complete remission (CR) will eventually relapse [2, 3].…”
Section: Introductionmentioning
confidence: 99%
“…Patients who expressed the bcr3 isoform appeared to have shorter disease‐free and overall survival durations, than those who expressed the bcr1 isoform (Jurcic et al. , 2001; Sucić et al. , 2002).…”
Section: Discussionmentioning
confidence: 93%
“…Moreover, in the present study structural cytogenetic aberrations were detected in 24/41 (58.5 %) of patients. [27] and Sucic et al [28] stressed on the point that not only t(15;17) is restricted to M3, but also practically, all M3 patients had this translocation at DNA levels even if karyotypically normal. Consistent with Grimwade and Solomon [29] and Chen et al [30] , this rearrangement is firmly established as remarkably APL associated cytogenetic abnormality classified among favorable group.…”
Section: Discussionmentioning
confidence: 99%